Patient-Based Therapeutics
AcuraStem is a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.
Patient Focused
learn about our work
Neurodegenerative Disease Areas
Latest News
PASADENA, Calif., March 10, 2026 — AcuraStem, a patient-based biotechnology company developing disease- modifying therapies for amyotrophic lateral sclerosis (ALS), today announced it has received a two-year research grant from Target ALS to advance therapeutics targeting SYF2, a recently identified regulator of TDP43 function. TDP-43 dysfunction is a central biological hallmark of ALS.
AcuraStem presented new poster data at the 36th International Symposium on ALS/MND, held December 5–7, 2025 in San Diego, USA, at the Loews Coronado Bay Resort. The Symposium, organized by the MND Association, is the largest annual conference dedicated to ALS and MND research and brings together researchers from around the world to share new findings.
At the symposium Frontiers in Neuroscience: Emerging Biology and Therapeutics, AcuraStem CEO Sam Alworth delivered a presentation titled “Using the iNeuroRx® Technology Platform to Develop Disease‑Modifying Treatments for ALS and FTD: Spotlight on UNC13A Candidate AS‑241.”